SOFINNOVA-PARTNERS
14.3.2024 11:01:28 CET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that its portfolio company, Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in the development of therapeutic peptides for rare endocrine and related diseases has entered into a definitive agreement with AstraZeneca for its acquisition, with an upfront purchase price of $800 million and a potential milestone payment of $250 million.
“We are proud of the remarkable achievements of our team, developing a therapeutic portfolio tackling unmet needs for rare endocrine and related diseases. Last year's Series C financing laid the foundation for the momentum with eneboparatide, propelling us forward to partner with Alexion, AstraZeneca Rare Disease, to bring innovative therapies to patients with rare endocrinology diseases globally. We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
“Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca. Leading Amolyt’s Series C financing round in January 2023 was an honor. This milestone demonstrates Sofinnova's investment thesis in action, showcasing our commitment to supporting innovative European companies during their critical growth stage. In Amolyt's case, it exemplifies our commitment to supporting a company developing groundbreaking solutions in a later stage of development for rare disease patients,” noted Cédric Moreau, Partner with the Sofinnova Crossover Strategy.
“This marks our second successful exit within the past year, reaffirming the strength of our Crossover Strategy and our longstanding presence in the endocrinology space. Thierry, is a visionary leader and embodies the serial biotech entrepreneurs we partner with,” added Antoine Papiernik, Managing Partner & Chairman of Sofinnova Partners.
Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said: “Chronic hypoparathyroid patients face a significant need for an alternative to current supportive therapies, which do not address the underlying hormone deficiency. As leaders in rare disease, Alexion is uniquely positioned to drive the late-stage development and global commercialisation of eneboparatide, which has the potential to lessen the often debilitating impact of low parathyroid hormone and avoid the risks of high-dose calcium supplementation. We believe this programme, together with Amolyt’s talented team, expertise, and earlier pipeline, will enable our expansion into rare endocrinology.”
Amolyt’s clinical pipeline includes differentiated therapeutic peptides for the treatment of underserved rare endocrine disease. Eneboparatide (AZP-3601) is an investigational daily subcutaneous injectable parathyroid hormone receptor 1 (PTHR1) agonist for the treatment of hypoparathyroidism, that is currently in Phase 3. AZP-3813 is a peptide growth hormone receptor antagonist for the potential treatment of acromegaly that is in Phase 1.
Terms of the agreement
Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis. This includes $800 million upfront at deal closing, plus the right for Amolyt Pharma’s shareholders to receive an additional contingent payment of $250 million payable upon achievement of a specified regulatory milestone.
Subject to the satisfaction of customary closing conditions in the acquisition agreement, including regulatory clearances, the transaction is expected to close by the end of the third quarter of 2024.
Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.
About Amolyt Pharma
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314071786/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Navan Selected by Investec to Modernize Global Travel Program12.10.2026 10:00:00 CEST | Press release
Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Investec, a leading international bank and wealth manager, to upgrade its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009977645/en/ Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program “As Investec continues its digital transformation, we’re excited to partner with an AI-first travel platform to increase adoption and improve operational efficiency,” said Lyndon Subroyen, Investec Group Chief Technology and Operating Officer. As a dual-listed company in the United Kingdom and South Africa, Investec sought a partner to consolidate its travel operations, reduce administrative work, and improve the booking experience for its workforce. Inve
Opensignal Launches World’s First Interactive Map of Satellite-to-Smartphone D2D Connections12.10.2026 10:00:00 CEST | Press release
Provides Independent, Real-World Global View of Direct-to-Device Activity Opensignal, a global independent consumer connectivity analytics and insights company, today launched the Opensignal D2D Satellite Map, the world’s first interactive, real-world depiction of where direct-to-device (D2D) satellite connections with smartphones are happening across the globe. Every point on the map, which will be updated monthly, represents a location where smartphones have connected to a D2D service since January 2026, extracted from Opensignal’s billions of real-world measurements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261011884935/en/ Opensignal D2D Satellite Map “D2D is reshaping who can deliver mobile coverage, and where, because the phone in your pocket can now reach a satellite directly. Until now, the industry has had to make decisions without knowing where momentum and adoption are real,” said Mike Sandy, President, Mark
Demand for Tech Services in Europe Continues to Surge, Led by AI-Driven Infrastructure Spending in Q3: ISG Index™12.10.2026 10:00:00 CEST | Press release
Combined market up 56%, as infrastructure spend more than doublesManaged services up 12%, as enterprises look for savings to fund AI Surging AI demand propelled Europe’s technology services market to a new high in the third quarter, as infrastructure spending more than doubled and traditional managed services grew by double digits, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, finds. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based infrastructure and software services) soared 56 percent—its fastest growth in eight years—to US $14.9 billion. It was the fourth straight quarter that combined ACV growth has exceeded 20 percent, averaging 39 percent in that span. “The European market is absolutely roaring right now,” said
Carta Secures Authorization to Operate as Fund Administrator and Transfer Agent in Luxembourg12.10.2026 10:00:00 CEST | Press release
The connected platform for private capital adds licensed fund administration and transfer agency to an ERP suite built for Luxembourg fund managers Carta, the connected platform and AI-native ecosystem for private capital, today announced it has received authorization to operate as a fully-licensed Specialised Professional of the Financial Sector (PSF) under the supervision of the CSSF (Commission de Surveillance du Secteur Financier) in Luxembourg. The authorization covers five statutory functions — registrar agent, corporate domiciliation agent, company incorporation and management services, administrative agent of the financial sector, and client communication agent — adding licensed fund administration and transfer agency directly to a platform already serving Luxembourg fund managers. Luxembourg is the second-largest fund domicile in the world, home to approximately 5,000 alternative investment fund entities managing over €1 trillion in assets. It is also the preferred jurisdictio
CIG to Showcase How Next-Generation Broadband Is Driving More Value with PON, Wi-Fi, Optics, and Edge AI at Network X 2026, Booth C4.12.10.2026 09:11:00 CEST | Press release
From a full line of Wi‑Fi 8 Products to industrial Edge AI, CIG will demonstrate technologies designed to create more value across the network Cambridge Industries Group (CIG), a global leader in broadband and optical connectivity technologies, will showcase its latest broadband, optical, and Edge AI platform innovation at Network X 2026, October 13-15 in Vienna. The exhibit will focus on a practical challenge for network operators: how to increase capacity while improving the experience. CIG’s broadband showcase will span the network from fiber access to the connected home. Visitors will see live demonstrations of Wi-Fi 8 capabilities in an XGS-PON gateway, previewing CIG’s approach to next-generation Wi-Fi: greater flexibility in platform design and more dependable performance in real-world subscriber environments. CIG will also demonstrate its prplWare 4.2.1-certified Wi-Fi 7 device. CIG will also showcase the AIU-100 Edge AI controller, initially focused on manufacturing applicatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom